Liberum Capital reaffirmed their hold rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Tuesday. They currently have a GBX 5,200 ($67.88) target price on the biopharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 4,800 ($62.66) price objective on shares of AstraZeneca plc in a report on Thursday, July 21st. Jefferies Group lifted their price objective on AstraZeneca plc from GBX 4,600 ($60.04) to GBX 4,800 ($62.66) and gave the stock a hold rating in a report on Thursday, July 14th. BNP Paribas reaffirmed an outperform rating and set a GBX 5,000 ($65.27) price objective on shares of AstraZeneca plc in a report on Wednesday, June 15th. HSBC set a GBX 4,815 ($62.85) price objective on AstraZeneca plc and gave the stock a neutral rating in a report on Tuesday, August 2nd. Finally, Beaufort Securities reissued a hold rating on shares of AstraZeneca plc in a report on Wednesday, August 10th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average price target of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) opened at 5087.00 on Tuesday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s market capitalization is GBX 64.35 billion. The company’s 50 day moving average price is GBX 5,004.64 and its 200 day moving average price is GBX 4,431.30.
The company also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were paid a dividend of GBX 68.70 ($0.90) per share. This represents a yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.